Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors
作者:Bingbing Zhao、Zhen Xiao、Jianguo Qi、Rong Luo、Zhou Lan、Yanzhuo Zhang、Xiaohan Hu、Qidong Tang、Pengwu Zheng、Shan Xu、Wufu Zhu
DOI:10.1016/j.ejmech.2018.11.069
日期:2019.2
(SBDD) and optimized the structure to obtain a series of potent and selective EGFRL858R/T790M inhibitors. The most potent compound 18e demonstrated excellent kinase inhibitory activity and selectivity for EGFRL858R/T790M double mutants and the IC50 value reached nanomolar level. The selectivity of 18e against wild-type EGFR was near to 200-fold. In addition, compound 18e also inhibited H1975 cells proliferation
第三代表皮生长因子受体(EGFR)L858R / T790M抑制剂仍然是治疗晚期非小细胞肺癌(NSCLC)的主要药物,这些药物已取得了显着的临床疗效。然而,仍然有许多患者患有由NSCLC引起的耐药性突变和药物副作用。在这项研究中,以分子模拟为指导,我们应用了基于结构的药物设计策略(SBDD),并优化了结构以获得一系列有效的选择性EGFR L858R / T790M抑制剂。最有效的化合物18e对EGFR L858R / T790M双突变体和IC 50具有极好的激酶抑制活性和选择性价值达到纳摩尔水平。18e对野生型EGFR的选择性接近200倍。此外,化合物18e在0.25μM的浓度下还抑制了H1975细胞在G2 / M期的增殖并诱导了细胞凋亡,这使其在潜在的肺癌研究中更具价值。